StÃ©phane Terry

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8660060/publications.pdf

Version: 2024-02-01

81 papers	4,555 citations	147801 31 h-index	144013 57 g-index
82 all docs	82 docs citations	82 times ranked	7450 citing authors

#	Article	IF	Citations
1	The Effect of Hypoxia and Hypoxia-Associated Pathways in the Regulation of Antitumor Response: Friends or Foes?. Frontiers in Immunology, 2022, 13, 828875.	4.8	31
2	Cancer stem-like cells evade CD8⁺CD103⁺ tumor-resident memory T (T_{RM}) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model. , 2022, 10, e004527.		12
3	Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition. Frontiers in Immunology, 2022, 13, 869676.	4.8	24
4	Tumor hypoxia: an important regulator of tumor progression or a potential modulator of tumor immunogenicity?. OncoImmunology, 2021, 10, 1974233.	4.6	13
5	Waterpipe smoke condensate influences epithelial to mesenchymal transition and interferes with the cytotoxic immune response in non-small cell lung cancer cell lines. Oncology Reports, 2021, 45, 879-890.	2.6	6
6	An Eight-Gene Hypoxia Signature Predicts Survival in Pancreatic Cancer and Is Associated With an Immunosuppressed Tumor Microenvironment. Frontiers in Immunology, 2021, 12, 680435.	4.8	28
7	Multifaceted Role of the Transforming Growth Factor Î² on Effector T Cells and the Implication for CAR-T Cell Therapy. Immuno, 2021, 1, 160-173.	1.5	4
8	Association of AXL and PD-L1 Expression with Clinical Outcomes in Patients with Advanced Renal Cell Carcinoma Treated with PD-1 Blockade. Clinical Cancer Research, 2021, 27, 6749-6760.	7.0	39
9	The Most Common VHL Point Mutation R167Q in Hereditary VHL Disease Interferes with Cell Plasticity Regulation. Cancers, 2021, 13, 3897.	3.7	4
10	Selection of tumorâ€'resistant variants following sustained natural killer cellâ€'mediated immune stress. Oncology Reports, 2021, 45, 582-594.	2.6	0
11	Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy. Seminars in Cancer Biology, 2020, 65, 140-154.	9.6	66
12	Hypoxia-driven intratumor heterogeneity and immune evasion. Cancer Letters, 2020, 492, 1-10.	7.2	39
13	AXL Targeting Abrogates Autophagic Flux and Induces Immunogenic Cell Death in Drug-Resistant Cancer Cells. Journal of Thoracic Oncology, 2020, 15, 973-999.	1.1	66
14	Decoding cancerâ€™s camouflage: epithelial-mesenchymal plasticity in resistance to immune checkpoint blockade. , 2020, 3, 832-853.		7
15	Tumor hypoxic stress, cellular plasticity and RKIP. , 2020, , 115-120.		0
16	Selection of tumorâ€'resistant variants following sustained natural killer cellâ€'mediated immune stress. Oncology Reports, 2020, 45, 582-594.	2.6	0
17	AXL Targeting Overcomes Human Lung Cancer Cell Resistance to NK- and CTL-Mediated Cytotoxicity. Cancer Immunology Research, 2019, 7, 1789-1802.	3.4	52
18	Abstract 1200: AXL targeting enhances lymphocyte-mediated cytotoxicity of lung cancer cells. , 2019, , .		0

#	Article	IF	Citations
19	Cancer Immunotherapy 2017 (Paris, France). Progress and challenges. Bulletin Du Cancer, 2018, 105, 537-541.	1.6	1
20	Tumor Hypoxia: A Key Determinant of Microenvironment Hostility and a Major Checkpoint during the Antitumor Response. Critical Reviews in Immunology, 2018, 38, 505-524.	0.5	19
21	Role of Hypoxic Stress in Regulating Tumor Immunogenicity, Resistance and Plasticity. International Journal of Molecular Sciences, 2018, 19, 3044.	4.1	64
22	Abstract 5754: Hypoxia-induced tumor plasticity and immune resistance involves an alteration of target recognition by a mechanism involving TGF-beta signaling. , 2018, , .		5
23	Fibroblast growth factor signaling as a bypass mechanism of the androgen receptor pathway: new perspectives for castration-resistant prostate cancer. Translational Cancer Research, 2018, 7, S449-S452.	1.0	0
24	Abstract 3774: BGB324, a selective small-molecule inhibitor of receptor tyrosine kinase AXL, targets tumor immune suppression and enhances immune checkpoint inhibitor efficacy. , 2018, , .		2
25	The immune checkpoint ligand PD-L1 is upregulated in EMT-activated human breast cancer cells by a mechanism involving ZEB-1 and miR-200. OncoImmunology, 2017, 6, e1263412.	4.6	193
26	Acquisition of tumor cell phenotypic diversity along the EMT spectrum under hypoxic pressure: Consequences on susceptibility to cell-mediated cytotoxicity. OncoImmunology, 2017, 6, e1271858.	4.6	61
27	New insights into the role of <scp>EMT</scp> in tumor immune escape. Molecular Oncology, 2017, 11, 824-846.	4.6	332
28	Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling. Cancer Letters, 2017, 410, 100-111.	7.2	28
29	Expression of CD94 byex vivo-differentiated NK cells correlates with thein vitroandin vivoacquisition of cytotoxic features. OncoImmunology, 2017, 6, e1346763.	4.6	4
30	Hypoxic Stress-Induced Tumor and Immune Plasticity, Suppression, and Impact on Tumor Heterogeneity. Frontiers in Immunology, 2017, 8, 1625.	4.8	79
31	Transcriptional response to hypoxic stress in melanoma and prognostic potential of GBE1 and BNIP3. Oncotarget, 2017, 8, 108786-108801.	1.8	22
32	Implication of NPM1 phosphorylation and preclinical evaluation of the nucleoprotein antagonist N6L in prostate cancer. Oncotarget, 2016, 7, 69397-69411.	1.8	17
33	Hypoxia: a key player in antitumor immune response. A Review in the Theme: Cellular Responses to Hypoxia. American Journal of Physiology - Cell Physiology, 2015, 309, C569-C579.	4.6	316
34	Clinical value of ERG, TFF3, and SPINK1 for molecular subtyping of prostate cancer. Cancer, 2015, 121, 1422-1430.	4.1	31
35	EMT in immuno-resistance. Oncoscience, 2015, 2, 841-842.	2.2	20
36	CRIPTO overexpression promotes mesenchymal differentiation in prostate carcinoma cells through parallel regulation of AKT and FGFR activities. Oncotarget, 2015, 6, 11994-12008.	1.8	20

#	Article	IF	Citations
37	Hypoxia: A Formidable Saboteur of the Anti-tumor Response. Resistance To Targeted Anti-cancer Therapeutics, 2015, , 115-142.	0.1	0
38	The Many Faces of Neuroendocrine Differentiation in Prostate Cancer Progression. Frontiers in Oncology, 2014, 4, 60.	2.8	194
39	Left lobe of the prostate during clinical prostate cancer screening: the dark side of the gland for right-handed examiners. Prostate Cancer and Prostatic Diseases, 2014, 17, 157-162.	3.9	0
40	Prospective Evaluation of an Extended 21-Core Biopsy Scheme as Initial Prostate Cancer Diagnostic Strategy. European Urology, 2014, 65, 154-161.	1.9	52
41	Cross Modulation between the Androgen Receptor Axis and Protocadherin-PC in Mediating Neuroendocrine Transdifferentiation and Therapeutic Resistance of Prostate Cancer. Neoplasia, 2013, 15, 761-IN22.	5.3	47
42	Detailed biopsy pathologic features as predictive factors for initial reclassification in prostate cancer patients eligible for active surveillance. Urologic Oncology: Seminars and Original Investigations, 2013, 31, 1060-1066.	1.6	16
43	Risk of repeat biopsy and prostate cancer detection after an initial extended negative biopsy: longitudinal followâ€up from a prospective trial. BJU International, 2013, 111, 988-996.	2.5	57
44	Lipidosterolic Extract of Serenoa Repens Modulates the Expression of Inflammation Related-Genes in Benign Prostatic Hyperplasia Epithelial and Stromal Cells. International Journal of Molecular Sciences, 2013, 14, 14301-14320.	4.1	27
45	Next-generation Prostate Cancer Biobanking. Diagnostic Molecular Pathology, 2012, 21, 61-68.	2.1	31
46	Oncogene-mediated alterations in chromatin conformation. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 9083-9088.	7.1	142
47	Androgens regulate Hedgehog signalling and proliferation in androgenâ€dependent prostate cells. International Journal of Cancer, 2012, 131, 1297-1306.	5.1	23
48	The Risk of Upstaged Disease Increases with Body Mass Index in Low-Risk Prostate Cancer Patients Eligible for Active Surveillance. European Urology, 2012, 61, 356-362.	1.9	28
49	Abstract A31: ERG-mediated alterations in chromatin conformation. Cancer Research, 2012, 72, A31-A31.	0.9	1
50	Abstract 2222: Oncogene-mediated alterations in chromatin conformation. , 2012, , .		0
51	Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Research, 2011, 21, 56-67.	5.5	179
52	1008 THE PCA3 SCORE ACCURATELY PREDICTS TUMOR VOLUME AND MIGHT HELP IN SELECTING PROSTATE CANCER PATIENTS FOR ACTIVE SURVEILLANCE. European Urology Supplements, 2011, 10, 313-314.	0.1	0
53	Molecular Characterization of Neuroendocrine Prostate Cancer and Identification of New Drug Targets. Cancer Discovery, 2011, 1, 487-495.	9.4	725
54	413 INHIBITION OF CASTRATION- AND CHEMO-RESISTANT PROSTATE TUMOR GROWTH BY THE MULTIVALENT PSEUDOPEPTIDE NUCANT 6L. Journal of Urology, 2011, 185, .	0.4	0

#	Article	IF	Citations
55	Prostate Cancer Antigen 3 Score Accurately Predicts Tumour Volume and Might Help in Selecting Prostate Cancer Patients for Active Surveillance. European Urology, 2011, 59, 422-429.	1.9	136
56	Abstract 957: Aurora kinase and N-myc are involved in neuroendocrine differentiation of prostate cancer and are new drug targets. , 2011, , .		0
57	Abstract 661: Efficiency of the multivalent pseudopeptide nucant 6L in castration- and chemo-resistant prostate cancers. , 2011, , .		0
58	Pathological findings and prostateâ€specific antigen outcomes after laparoscopic radical prostatectomy for highâ€risk prostate cancer. BJU International, 2010, 106, 86-90.	2.5	21
59	Class III Î²-Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy. Cancer Research, 2010, 70, 9253-9264.	0.9	135
60	Pilot trial of adjuvant paclitaxel plus androgen deprivation for patients with high-risk prostate cancer after radical prostatectomy: results on toxicity, side effects and quality-of-life. Prostate Cancer and Prostatic Diseases, 2010, 13, 97-101.	3.9	8
61	376 HEDGEHOG/GLI SUPPORTS ANDROGEN SIGNALING IN ANDROGEN DEPRIVED AND ANDROGEN INDEPENDENT PROSTATE CANCER CELLS. Journal of Urology, 2010, 183, .	0.4	0
62	FusionSeq: a modular framework for finding gene fusions by analyzing paired-end RNA-sequencing data. Genome Biology, 2010, 11, R104.	8.8	137
63	Hedgehog/Gli supports androgen signaling in androgen deprived and androgen independent prostate cancer cells. Molecular Cancer, 2010, 9, 89.	19.2	48
64	Abstract 2743: Accelerating the exploration of novel gene fusion events in prostate cancer. , 2010, , .		0
65	Abstract 5472: Class III beta-tubulin in castration resistant human prostate cancer. , 2010, , .		0
66	Next generation RNA sequencing of neuroendocrine prostate cancer.. Journal of Clinical Oncology, 2010, 28, e15010-e15010.	1.6	0
67	Prostate Cancer Detection Rate in Patients with Repeated Extended 21-Sample Needle Biopsy. European Urology, 2009, 55, 600-609.	1.9	114
68	Inflammation in benign prostatic hyperplasia: A 282 patients' immunohistochemical analysis. Prostate, 2009, 69, 1774-1780.	2.3	227
69	Increased expression of class III Î²-tubulin in castration-resistant human prostate cancer. British Journal of Cancer, 2009, 101, 951-956.	6.4	76
70	348 INFLAMMATION IN PROSTATIC TISUE IS ASSOCIATED WITH SYMPTOM ATIC BPH, IPSS AND PROSTATE VOLUME!. European Urology Supplements, 2009, 8, 207.	0.1	0
71	INFLAMMATION IN PROSTATIC TISSUE IS ASSOCIATED WITH SYMPTOMATIC BPH, IPSS AND PROSTATE VOLUME!. Journal of Urology, 2009, 181, 504-504.	0.4	5
72	Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. Journal of Pathology, 2008, 216, 460-470.	4.5	60

#	Article	IF	Citations
73	THE EFFECT OF PROTOCADHERIN-PC (PCDH-PC) EXPRESSION ON THE INVASIVE PHENOTYPE OF PROSTATE CANCER CELLS. Journal of Urology, 2008, 179, 425-425.	0.4	0
74	Neuroendocrine Differentiation in Prostate Cancer: From Lab to Bedside. Urologia Internationalis, 2007, 79, 287-296.	1.3	44
75	The NF-ÎºB/IL-6 pathway in metastatic androgen-independent prostate cancer: new therapeutic approaches?. World Journal of Urology, 2007, 25, 477-489.	2.2	64
76	1012: Adjuvant Androgen Deprivation and Chemotherapy for Patients with High Risk Prostate Cancer Progression After Radical Prostatectomy: Preliminary Study on Toxicity and Side Effects. Journal of Urology, 2007, 177, 334-334.	0.4	0
77	Protocadherin-PC promotes androgen-independent prostate cancer cell growth. Prostate, 2006, 66, 1100-1113.	2.3	35
78	Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene, 2006, 25, 3436-3444.	5.9	116
79	Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. Journal of Cellular Biochemistry, 2006, 99, 402-410.	2.6	91
80	417: The Human Androgen Receptor Gene is a Primary Target of the WNT Signaling Pathway. Journal of Urology, 2006, 175, 136-136.	0.4	0
81	A Human- and Male-Specific Protocadherin that Acts through the Wnt Signaling Pathway to Induce Neuroendocrine Transdifferentiation of Prostate Cancer Cells. Cancer Research, 2005, 65, 5263-5271.	0.9	111